Investigational drug · Phase 3
REGN1909
Also called: Mevonlerbart
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Conjunctivitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "REGN1909"
First trial start
2024
Nov 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN1909", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Conjunctivitis
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN1909" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07675811 · 570 participants (planned) · Start Jul 31, 2026 · Primary completion May 31, 2029
Drug: REGN-2Cat; Freneslerbart and 2 more · For: Allergic Conjunctivitis
Sites: Long Beach, California; Andover, Massachusetts
- A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat AllergyPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06602726 · 64 participants · Start Nov 6, 2024 · Primary completion May 10, 2025
Drug: REGN1908; REGN1909 and 1 more · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts; Kingston, Canada; Ottawa, Canada · 4 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03838731 · 56 participants · Start Feb 12, 2019 · Primary completion Dec 21, 2019
Drug: REGN1908-1909; Placebo · For: Cat Allergy; Mild Asthma
Sites: Strasbourg, France
Newest research
PubMed records naming it or its code names, newest first.
- REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics.
Kamal MA, Dingman R, Wang CQ, et al. · Clin Transl Sci 2021
- Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Shamji MH, Singh I, Layhadi JA, et al. · Am J Respir Crit Care Med 2021
Also in development for Allergic Conjunctivitis
- REGN1908FreneslerbartPhase 32 trials
Regeneron · Allergic Conjunctivitis
- REGN5713BremzalerbartPhase 31 trial
Regeneron · Allergic Conjunctivitis
- REGN5715AtisnolerbartPhase 31 trial
Regeneron · Allergic Conjunctivitis
- TL-925Phase 23 trials
Telios Pharma, Inc. · Allergic Conjunctivitis, Allergic Conjunctivitis of Both Eyes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.